Revised SPC: Lemtrada (alemtuzumab) 12 mg concentrate for solution for infusion
SPCs revised to warn that Epstein-Barr virus (EBV) infection, including reactivation and severe and sometimes fatal EBV hepatitis cases, has been reported in patients’ treated with alemtuzumab.
Source:
electronic Medicines compendium